Filtered By:
Procedure: Radiography

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 443 results found since Jan 2013.

Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report
Tuberk Toraks. 2022 Jun;70(2):215-219. doi: 10.5578/tt.20229815.ABSTRACTAllergic bronchopulmonary aspergillosis (ABPA) is a lung disease characterized by a hypersensitivity reaction to Aspergillus fumigatus. Allergic bronchopulmonary aspergillosis is characterized by increased serum IgE levels, peripheral blood eosinophilia and radiographic pulmonary infiltrates, central bronchiectasis, and mucus plugs. Mepolizumab, a monoclonal interleukin (IL)-5 antibody, reduces eosinophilic inflammation and improves symptom control in severe eosinophilic asthma. A 74-year-old male patient arrived at our allergy outpatient clinic compla...
Source: Tuberkuloz ve Toraks - July 5, 2022 Category: Respiratory Medicine Authors: Mehmet Erdem Çakmak Source Type: research

Similar clinical and radiographic outcomes after two different hypoallergenic medial unicompartmental knee in patients with metal allergy
ConclusionsBoth TiNbN and Oxinium UKA procedures enabled patients from good to excellent clinical and radiographic outcomes after the final follow-up, regardless of the age, gender, BMI bearing type, and implant size.Level of evidence: Level IIComparative study.
Source: European Journal of Orthopaedic Surgery and Traumatology - May 29, 2022 Category: Orthopaedics Source Type: research

Use of intraoperative frontal sinus mometasone ‐eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polyps
ConclusionAlthough patients who received intraoperative frontal MES had significantly higher pre-ESS MM IL-13 and ECP, patients who received frontal MES had lower concentrations of IL-4 and IL-13 than those who did not at a median of 8 months post-ESS. However, these changes did not correspond to significantly different measures of symptomatic or radiographic disease severity.
Source: International Forum of Allergy and Rhinology - May 20, 2022 Category: Allergy & Immunology Authors: Alexander L. Schneider, Samuel D. Racette, Anthony K. Kang, Abhita T. Reddy, Julia H. Huang, David S. Lehmann, Caroline P.E. Price, Jacob G. Eide, Samuel R. Rodeghiero, David B. Conley, Kevin C. Welch, Robert C. Kern, Stephanie Shintani ‐Smi Tags: ORIGINAL ARTICLE Source Type: research